The Biomarker Gold Rush Has a Counterfeiting Problem
The omics pipeline rewards discovery. It rarely rewards validation. Here is why that gap is predictable, measurable, and systematically mispriced in most due diligence frameworks.
Part I
→
Part II
Your Biomarker Report Is Answering a Question You Didn’t Ask
What your omics panel is actually measuring — and what it isn’t
→
Part III
What omics gets right — and how it gets there
Part Three of a series on omics-based biomarkers
→
Part IV
You’re spending real money on health data. Here’s how to actually use it.
Part Four of a series on omics-based biomarkers
→
Part V
The Biomarker Market Has a Story Problem
Part Five of a series on omics-based biomarkers
→